Methodological evaluation of HPV-DNA and liquid-based cytology test for cervical cancer screening
AIM:To evaluate the clinical value of human papil-lomavirns (HPV) DNA test and liquid-based cytology test (LCT) and their combined analysis for cervical cancer screening. METHODS: Hybrid capture Ⅱ (HC-Ⅱ) for HPV-DNA and LCT were performed in 1200 cases by double blind method. The women with abnormal or squamons findings on colposcopy received biopsy. After biopsy under colpescopy, the results of the pathology examination was taken as the final diagnosis in screening cervical cancer. RESULTS: A total of 156 patients received biopsy in this study. Of the 156 patients, 3 were diagnosed as having cervical cancer, 9 cervical intraep ithelialneoplasia CINⅢ, 19 CINⅡ, 49 CINⅠ, and 63 other diseases(chrenic cervititis and metaplasia). The positive rates of HPV-DNA and LCT were 16.8% and 11.8%, respectively. The positive rates of HPV combined with LCT were 21.2% in parallel test and 7.4% in serial test. All the positive rates increased with the increase of cervical lesions grade (P<0.005). The areas under receiver operating characteristic(ROC) curves in each screening test for screening high grade cervical lesions were 0.919, 0.921,0.904 and 0.926, with no statistical differences (P>0.05). CONCLUSION: Both HC-Ⅱ HPV test and LCT are valuable for screening cervical cancer. The combined detection by both HC-Ⅱ HPV and LCT will not significantly improve the detection rate in cervical cancer screening, but may increase the cost of the screening.
NETL
NSTL
万方数据
维普
